Cargando…

Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States

BACKGROUND: Atrial fibrillation (AF) affects a significant proportion of the American population and increases ischemic stroke risk by 4- to 5-fold. Oral vitamin K antagonists, such as warfarin, can significantly reduce this stroke risk but can be difficult to dose and monitor. Previous research on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, William L., Cios, Deborah A., Sander, Stephen D., Coleman, Craig I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437339/ https://www.ncbi.nlm.nih.gov/pubmed/19326955 http://dx.doi.org/10.18553/jmcp.2009.15.3.244

Ejemplares similares

Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis
por: Baczek, Victoria L, et al.
Publicado: (2012)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States
por: Jain, Rahul, et al.
Publicado: (2018)

Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits
por: Fitzgerald, P., et al.
Publicado: (2020)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
por: Sood, Nitesh, et al.
Publicado: (2023)

Low Quality of Warfarin Therapy is Associated With Female Gender but Not With Polypharmacy in Patients With Atrial Fibrillation
por: Takamoto, Kojiro, et al.
Publicado: (2021)

Seasonal Variation of Atrial Fibrillation Admission and Quality of Care in the United States
por: Sheehy, Shanshan, et al.
Publicado: (2022)

Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
por: Berger, Jeffrey S., et al.
Publicado: (2021)

Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
por: Hansen, Carolina Malta, et al.
Publicado: (2012)

Improving outpatient warfarin use for hospitalized patients with atrial fibrillation
por: Touchette, Daniel R., et al.
Publicado: (2008)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Characteristics of warfarin under-prescription in older adults with atrial fibrillation
por: Rashid, Sana, et al.
Publicado: (2021)

Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians
por: Nicholls, Stuart G, et al.
Publicado: (2014)

Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices
por: Ewen, Edward, et al.
Publicado: (2012)

Warfarin Use and Risk of Stroke in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Meta-Analysis
por: Lee, Meng, et al.
Publicado: (2016)

Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis
por: Nochaiwong, Surapon, et al.
Publicado: (2016)

Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies
por: Liu, Gang, et al.
Publicado: (2015)

Stability of High‐Quality Warfarin Anticoagulation in a Community‐Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
por: Dallalzadeh, Liane O., et al.
Publicado: (2016)

Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic
por: Lee, Siew Ling, et al.
Publicado: (2021)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty
por: Juma, Salima, et al.
Publicado: (2013)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
por: Simon, Teresa A., et al.
Publicado: (2016)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Atrial fibrillation in advanced renal failure: are there alternative solutions to warfarin-dicumarol?
por: Rossini, Roberta, et al.
Publicado: (2021)

Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry
por: Liang, Hai-Feng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ae3df1cdh0cvkob2ce4016emjn